A team of researchers co-led by our MedChemNet Leader Atanas Atanasov (University of Vienna, Austria) have prepared a comprehensive review of the latest advances in natural product-derived drug discovery, giving important insights into the future of the field.
Researchers from the University of California, Los Angeles (CA, USA) and Shanghai Jiao Tong University (Shanghai, China) have utilized a novel technique to study the potential of different drug combinations as faster and more effective treatment options for tuberculosis.
Researchers co-led by scientists from the University of Kent (Canterbury, UK) and Goethe University (Frankfurt, Germany) have identified a first step in the design of a new generation of anti-cancer therapeutics.
Researchers from the University of Toronto Faculty of Applied Science & Engineering (Canada) have developed a novel way to grow realistic human tissue outside the body, providing a powerful new platform for drug discovery and testing, and with potential applications for eventual repair or replacement of damaged organs.
Researchers from the Walter and Eliza Hall Institute (Victoria, Australia) have discovered that the best treatment for the most deadly form of blood cancer may be to combine two recently developed drugs.
A team from the Walter and Eliza Hall Institute (Melbourne, Australia) have resolved a mystery about the action of a novel class of anti-cancer drugs, nutlins, with potential implications for future cancer treatments.
Jack Scannell from Oxford University's Centre for the Advancement of Sustainable Medical Innovation (UK) and consultant Jim Bosley have used mathematical tools to address the hypothesis that poor choices of study method are the root of unsustainably expensive drug discovery.
A team from the Johns Hopkins Bloomberg School of Public Health (MD, USA) has developed tiny brain-like structures, made up of human neurons and cells, with the potential to dramatically change how drugs for neurological conditions are evaluated.